Triple-negative breast cancer: recent treatment advances.

F1000Res · 2019 · PMC6681627 · PMID 31448088

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Interim OS analysis (60% of events) already showed a trend towards the atezolizumab and taxane combination with median OS values of 21.3 and 17.6 months (stratified HR 0.84, 95% CI 0.69–1.02) 77 .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.